Profile of the BD HPV OnclarityTM assay

References

• Zur Hausen H. Papillomaviruses in the causation of human cancers—a brief historical account. Virology. 2009;384:260–265.
   PubMed Web of Science ®Google Scholar
• Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012 Nov 20;30(Suppl 5):F88–99. Review.
   PubMed Web of Science ®Google Scholar
• Ronco G, Dillner J, Elfstrom KM, et al.; International HPVswg. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524–532.
   PubMed Web of Science ®Google Scholar
• Tota JE, Bentley J, Blake J, et al. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: acting on evidence to change the current paradigm. Prev Med. 2017;98:5–14.
   PubMed Web of Science ®Google Scholar
• Poljak M, Kocjan BJ, Oštrbenk A, et al. Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. J Clin Virol. 2016 Mar;76(Suppl 1):S3–S13. Epub 2015 Nov 5.
   PubMedGoogle Scholar
• Arbyn M, Snijders PJ, Meijer CJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect. 2015 Sep;21(9):817–826.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Hillemanns P (2018). HPV assays validated for primary cervical cancer screening. 55 Available from: www.HPVWorld.com
   Google Scholar
• Heideman DA, Hesselink AT, Berkhof J, et al. Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol. 2011 Nov;49(11):3983–3985.
   PubMed Web of Science ®Google Scholar
• Carozzi FM, Burroni E, Bisanzi S, et al. Comparison of clinical performance of abbott realtime high risk HPV test with that of hybrid capture 2 assay in a screening setting. J Clin Microbiol. 2011 Apr;49(4):1446–1451.
   PubMed Web of Science ®Google Scholar
• Boers A, Wang R, Slagter-Menkema L, et al. Clinical validation of the cervista HPV HR test according to the international guidelines for human papillomavirus test requirements for cervical cancer screening. J Clin Microbiol. 2014 Dec;52(12):4391–4393.
   PubMed Web of Science ®Google Scholar
• Heard I, Cuschieri K, Geraets DT, et al. Clinical and analytical performance of the PapilloCheck HPV-screening assay using the VALGENT framework. J Clin Virol. 2016 Aug;81:6–11.
   PubMed Web of Science ®Google Scholar
• Hesselink AT, Berkhof J, van der Salm ML, et al. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region. J Clin Microbiol. 2014 Mar;52(3):890–896.
   PubMed Web of Science ®Google Scholar
• Hesselink AT, Sahli R, Berkhof J, et al. Clinical validation of anyplex™ II HPV HR detection according to the guidelines for HPV test requirements for cervical cancer screening. J Clin Virol. 2016 Mar;76:36–39.
   PubMed Web of Science ®Google Scholar
• Cuschieri K, Geraets D, Cuzick J, et al. Performance of a cartridge-based assay for detection of clinically significant human papillomavirus (HPV) infection: lessons from VALGENT (Validation of HPV Genotyping Tests). J Clin Microbiol. 2016 Sep;54(9):2337–2342.
   PubMed Web of Science ®Google Scholar
• Viti J, Poljak M, Oštrbenk A, et al. Validation of EUROArray HPV test using the VALGENT framework. J Clin Virol. 2018 Nov;108:38–42.
   PubMed Web of Science ®Google Scholar
• Iacobellis M, Violante C, Notarachille G, et al. Clinical validation of REALQUALITY RQ-HPV screen according to the international guidelines for human papillomavirus DNA test requirements for cervical screening. Virol J. 2018 Mar 20;15(1):48.
   PubMedGoogle Scholar
• Heideman DA, Hesselink AT, van Kemenade FJ, et al. The aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening. J Clin Microbiol. 2013 Nov;51(11):3653–3657.
   PubMed Web of Science ®Google Scholar
• Cox JT, Castle PE, Behrens CM, et al.; Athena HPV Study Group. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol. 2013 Mar;208(3):184.e1-184.e11.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Xu L, Verdoodt F, et al. Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: A systematic review and meta-analysis. Ann Intern Med. 2017 Jan 17;166(2):118–127.
   PubMed Web of Science ®Google Scholar
• Wright TC, Stoler MH, Behrens CM, et al. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015 Feb;136(2):189–197.
   PubMed Web of Science ®Google Scholar
• Schiffman M, Vaughan LM, Raine-Bennett TR, et al. A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Gynecol Oncol. 2015 Sep;138(3):573–578.
   PubMed Web of Science ®Google Scholar
• Xi LF, Schiffman M, Koutsky LA, et al. Variant-specific persistence of infections with human papillomavirus Types 31, 33, 45, 56 and 58 and risk of cervical intraepithelial neoplasia. Int J Cancer. 2016 Sep 1;139(5):1098–1105.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Redman CWE, Verdoodt F, et al. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncol. 2017 Dec;18(12):1665–1679.
   PubMed Web of Science ®Google Scholar
• Bottari F, Iacobone AD, Boveri S, et al. Onclarity human papillomavirus extended genotyping in the management of cervical intraepithelial neoplasia 2+ lesions. J Low Genit Tract Dis. 2019 Jan;23(1):39–42.
   PubMed Web of Science ®Google Scholar
• Egli-Gany D, Spaar Zographos A, Diebold J, et al.; CIN3+plus study group. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study. BMC Cancer. 2019 Jan 30;19(1):111.
   PubMedGoogle Scholar
• Stoler MH, Wright TC Jr., Parvu V, et al. The onclarity human papillomavirus trial: design, methods, and baseline results. Gynecol Oncol. 2018;149:498–505.
   PubMed Web of Science ®Google Scholar
• Ejegod D, Bottari F, Pedersen H, et al. The BD onclarity HPV assay on samples collected in surepath medium meets the international guidelines for human papillomavirus test requirements for cervical screening. J Clin Microbiol. 2016;54:2267–2272.
   PubMed Web of Science ®Google Scholar
• Cuschieri K, Geraets DT, Moore C, et al. Clinical and analytical performance of the onclarity HPV assay using the VALGENT framework. J Clin Microbiol. 2015 Oct;53(10):3272–3279.
   PubMed Web of Science ®Google Scholar
• Available from: https://www.fda.gov/medical-devices/recently-approved-devices/bd-onclarity-hpv-assay-p160037
   Google Scholar
• Wright TC Jr., Stoler MH, Parvu V, et al. Detection of cervical neoplasia by human papillomavirus testing in an atypical squamous cells-undetermined significance population: results of the becton dickinson onclarity trial. Am J Clin Pathol. 2018. DOI:10.1093/ajcp/aqy084
   Web of Science ®Google Scholar
• Muñoz N, Bosch FX, Castellsagué X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004 Aug 20;111(2):278–285.
   PubMed Web of Science ®Google Scholar
• Bonde J, Bottari F, Parvu V, et al. BAYESIAN ANALYSIS OF BASELINE RISK OF CIN2 AND ≥CIN3 BY HPV GENOTYPE IN A EUROPEAN REFERRAL COHORT. Int J Cancer. 2019 Mar 20.
   PubMedGoogle Scholar
• Arbyn M, Peeters E, Benoy I, et al. VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples. J Clin Virol. 2018 Oct;107:52–56.
   PubMed Web of Science ®Google Scholar
• Castro FA, Koshiol J, Quint W, et al. Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods. BMC Infect Dis. 2015 Nov;25(15):544.
   Google Scholar